18f -偏氟苯胍PET成像在神经母细胞瘤中的病变分析

Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak
{"title":"18f -偏氟苯胍PET成像在神经母细胞瘤中的病变分析","authors":"Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak","doi":"10.2967/jnumed.125.269833","DOIUrl":null,"url":null,"abstract":"<p>A PET analog of metaiodobenzylguanidine (MIBG)—<sup>18</sup>F-metafluorobenzylguanidine (<sup>18</sup>F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of <sup>18</sup>F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with <sup>18</sup>F-MFBG imaging in patients with neuroblastoma compared with <sup>123</sup>I-MIBG imaging. <strong>Methods:</strong> We analyzed concurrent <sup>18</sup>F-MFBG and <sup>123</sup>I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of <sup>18</sup>F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an <sup>123</sup>I-MIBG scan within 4 wk of <sup>18</sup>F-MFBG imaging without any intervening therapy. <sup>123</sup>I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both <sup>123</sup>I-MIBG scans, equivalent scores were ascertained for <sup>18</sup>F-MFBG imaging, and scores were then compared. <strong>Results:</strong> All patients with a positive <sup>123</sup>I-MIBG scan had positive <sup>18</sup>F-MFBG imaging. In 2 patients, both <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG scans were negative. In 1 patient, the <sup>18</sup>F-MFBG scan was positive, whereas the <sup>123</sup>I-MIBG scan was negative. In 30 of 40 scans, <sup>18</sup>F-MFBG showed more sites than did <sup>123</sup>I-MIBG. Overall, more lesions were noted on the <sup>18</sup>F-MFBG scans (mean, 18; range 0–61) compared with the <sup>123</sup>I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for <sup>18</sup>F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for <sup>123</sup>I-MIBG (range, 0–22). Of the 273 <sup>18</sup>F-MFBG–positive/<sup>123</sup>I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. <strong>Conclusion:</strong> <sup>18</sup>F-MFBG PET offers faster imaging and superior detection compared with <sup>123</sup>I-MIBG imaging. <sup>18</sup>F-MFBG had high concordance with <sup>123</sup>I-MIBG at the patient level and showed more lesions in most patients. <sup>18</sup>F-MFBG is an attractive alternative to <sup>123</sup>I-MIBG.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma\",\"authors\":\"Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak\",\"doi\":\"10.2967/jnumed.125.269833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A PET analog of metaiodobenzylguanidine (MIBG)—<sup>18</sup>F-metafluorobenzylguanidine (<sup>18</sup>F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of <sup>18</sup>F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with <sup>18</sup>F-MFBG imaging in patients with neuroblastoma compared with <sup>123</sup>I-MIBG imaging. <strong>Methods:</strong> We analyzed concurrent <sup>18</sup>F-MFBG and <sup>123</sup>I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of <sup>18</sup>F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an <sup>123</sup>I-MIBG scan within 4 wk of <sup>18</sup>F-MFBG imaging without any intervening therapy. <sup>123</sup>I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both <sup>123</sup>I-MIBG scans, equivalent scores were ascertained for <sup>18</sup>F-MFBG imaging, and scores were then compared. <strong>Results:</strong> All patients with a positive <sup>123</sup>I-MIBG scan had positive <sup>18</sup>F-MFBG imaging. In 2 patients, both <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG scans were negative. In 1 patient, the <sup>18</sup>F-MFBG scan was positive, whereas the <sup>123</sup>I-MIBG scan was negative. In 30 of 40 scans, <sup>18</sup>F-MFBG showed more sites than did <sup>123</sup>I-MIBG. Overall, more lesions were noted on the <sup>18</sup>F-MFBG scans (mean, 18; range 0–61) compared with the <sup>123</sup>I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for <sup>18</sup>F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for <sup>123</sup>I-MIBG (range, 0–22). Of the 273 <sup>18</sup>F-MFBG–positive/<sup>123</sup>I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. <strong>Conclusion:</strong> <sup>18</sup>F-MFBG PET offers faster imaging and superior detection compared with <sup>123</sup>I-MIBG imaging. <sup>18</sup>F-MFBG had high concordance with <sup>123</sup>I-MIBG at the patient level and showed more lesions in most patients. <sup>18</sup>F-MFBG is an attractive alternative to <sup>123</sup>I-MIBG.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.125.269833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.269833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

一种metaiodobenzylguanidine (MIBG)的PET类似物- 18f - metfluorobenzylguanidine (18F-MFBG) -允许快速的当日成像。我们之前报道了18F-MFBG PET成像在神经内分泌肿瘤患者中的安全性和可行性。我们现在报告了一项综合分析,与123I-MIBG成像相比,18F-MFBG成像在神经母细胞瘤患者中的病变检测。方法:我们分析了37例患者的18F-MFBG和123I-MIBG同时扫描(40次成对扫描)。复发或难治性神经母细胞瘤患者也包括在内。患者静脉注射74.11 ~ 465.83 MBq (2.0 ~ 12.6 mCi)的18F-MFBG,注射后60 min行影像学检查。所有患者在18F-MFBG成像后4周内进行123I-MIBG扫描,未进行任何干预治疗。123I-MIBG扫描包括胸部、腹部和骨盆的全身平面和SPECT/CT。所有检测到的病变都被记录下来。评估123I-MIBG和18F-MFBG结果的一致性和不一致性。对123I-MIBG扫描分配修改的居里分数,对18F-MFBG成像确定相同的分数,然后比较分数。结果:所有123I-MIBG扫描阳性的患者均有18F-MFBG成像阳性。2例患者123I-MIBG和18F-MFBG扫描均为阴性。在1例患者中,18F-MFBG扫描为阳性,而123I-MIBG扫描为阴性。在40次扫描中的30次中,18F-MFBG比123I-MIBG显示出更多的位点。总的来说,与123I-MIBG扫描(平均12个,范围0-44)相比,18F-MFBG扫描(平均18个,范围0-61)发现了更多的病变,455个病变是一致的。18F-MFBG的居里得分更高,平均为11分(范围0-25),而123I-MIBG的居里得分为8分(范围0-22)。在273例18f - mfbg阳性/ 123i - mibg阴性病变中,对30例患者的234个病变进行了随访临床和影像学评估,其中100%确认为真阳性。结论:与123I-MIBG成像相比,18F-MFBG PET成像速度更快,检测效果更好。18F-MFBG与123I-MIBG在患者水平上一致性较高,且多数患者病变较多。18F-MFBG是123I-MIBG的一个有吸引力的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma

A PET analog of metaiodobenzylguanidine (MIBG)—18F-metafluorobenzylguanidine (18F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of 18F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with 18F-MFBG imaging in patients with neuroblastoma compared with 123I-MIBG imaging. Methods: We analyzed concurrent 18F-MFBG and 123I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of 18F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an 123I-MIBG scan within 4 wk of 18F-MFBG imaging without any intervening therapy. 123I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. 123I-MIBG and 18F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both 123I-MIBG scans, equivalent scores were ascertained for 18F-MFBG imaging, and scores were then compared. Results: All patients with a positive 123I-MIBG scan had positive 18F-MFBG imaging. In 2 patients, both 123I-MIBG and 18F-MFBG scans were negative. In 1 patient, the 18F-MFBG scan was positive, whereas the 123I-MIBG scan was negative. In 30 of 40 scans, 18F-MFBG showed more sites than did 123I-MIBG. Overall, more lesions were noted on the 18F-MFBG scans (mean, 18; range 0–61) compared with the 123I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for 18F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for 123I-MIBG (range, 0–22). Of the 273 18F-MFBG–positive/123I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. Conclusion: 18F-MFBG PET offers faster imaging and superior detection compared with 123I-MIBG imaging. 18F-MFBG had high concordance with 123I-MIBG at the patient level and showed more lesions in most patients. 18F-MFBG is an attractive alternative to 123I-MIBG.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信